NOTE! 1. NFA (Not Financial Advice!) 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NE...
70761249
:
Can VERI make a breakthrough in the short term? The recent wildfires in Southern California are really heartbreaking, causing significant disappointment in the credibility of the media and government.
$Jasper Therapeutics (JSPR.US)$ Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria Wednesday, 8th January at 7:00 am Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Com...
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Jasper Therapeutics Stock Forum
Jasper's Briquilimab Takes Center Stage: 6 Key Data Presentations to Reveal Treatment Breakthrough at AAAAI 2025
Why is this so cheap if they rate it Strong Buy $62.78
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Wednesday, 8th January at 7:00 am
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points
100% (N=3) Com...
No comment yet